The Pharmaceutical Cold War: India Is Europe's Drug Supply Lifeline — And It's Vulnerable

Europe gets 70-80% of its generic medicine from India. The US pharmaceutical tariff threat and India's own policy changes are creating supply chain risks that European health ministries are quietly worried about.

The European pharmaceutical supply chain has a specific vulnerability that sits uncomfortably between US trade policy, India's domestic pharmaceutical policy, and Europe's own post-COVID supply chain resilience agenda. Understanding this vulnerability requires understanding that Europe depends on India for approximately 70-80 percent of its generic medicine supply — a concentration that reflects genuine Indian pharmaceutical manufacturing excellence but also creates a single-point-of-failure risk that health ministries are quietly documenting.

The US pharmaceutical tariff scenario — tariffs potentially reaching 200 percent — creates an indirect European risk through a mechanism that is not immediately obvious. If US tariffs make the US market less attractive for Indian pharmaceutical manufacturers, those manufacturers face a binary choice: absorb lower returns on US market sales, or redirect supply toward more profitable markets. European markets may compete with the redirected US volume for Indian pharmaceutical output, potentially tightening European supply conditions even though the tariff is US-directed.

Simultaneously, India's own pharmaceutical policy has been shifting toward prioritising domestic supply security — a post-COVID lesson shared by every major economy. Indian pharmaceutical regulation has been imposing stricter export restrictions on specific APIs and finished medicines during shortage conditions, exactly the conditions that an Iran war energy crisis might create. A global shortage of energy-intensive pharmaceutical inputs could trigger Indian export restrictions that affect European supply.

For European health security strategy, the Indian pharmaceutical dependency is the healthcare equivalent of the Russian gas dependency: a commercially rational concentration in a reliable supplier that creates strategic vulnerability when the reliability of that supplier is questioned or when the supplier's ability to fulfill all its commitments simultaneously is strained.

The European Commission's pharmaceutical supply security strategy — which calls for European domestic production of certain critical medicines — is the correct long-term response. The timeframe for its implementation is measured in years. The vulnerability it is designed to address is present now.